# Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

> **NCT00952237** · PHASE1 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 13 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Hodgkin's Disease
- Multiple Myeloma
- Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)
- Leukemia

## Interventions

- **DRUG:** GM-CSF
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT00952237
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952237, "Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00952237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*